AstraZeneca received positive news from the late-stage clinical trial of its drug, Enhertu, used to treat metastatic (also known as stage IV) breast cancer. The treatment resulted in a “statistically significant and clinically meaningful improvement” in the survival rates of people with this developed stage of breast cancer.
Metastatic breast cancer accounts for over half of all breast cancer cases and occurs when cancer has spread to vital organs in addition to the breast tissue, detrimentally affecting the lungs, liver, brain, or bones. At present, there is no cure for this stage of cancer, though some patients have success with treatments such as chemotherapy and are able to extend their lives. Given the high prevalence of breast cancer, which causes around 685,000 deaths each year globally, any treatments which improve survival rates are highly valuable.
Enhertu demonstrated significant improvement in both progression-free survival (PFS rates) as well as overall survival rates, meeting the trial’s primary and secondary endpoints.
AstraZeneca worked alongside a Japanese firm to clinically test Enhertu, successfully demonstrating that the drug is the first of its kind to significantly benefit patients of metastatic cancer. Executives from both firms anticipate the drug becoming a staple in breast cancer treatment.
Following the release of the trial’s significant data, AstraZeneca’s shares increased by 4 percent, demonstrating the anticipated hike in the value of the breakthrough drug.
Want to Learn More?
In addition to keeping you up to date on all things clinical trials, we also act as a digital CRO with a specific focus on patient recruitment and retention. We believe that patient recruitment and study startup (especially study design and study material) are heavily intertwined. After all, study design can make or break clinical trials, and the patient perspective should be considered when designing studies to ensure that patient targets are met not only on time but also on budget.
For Citruslabs, patient recruitment starts with study design and ends with trial completion. We recruit patients through our network of health apps, which enables you to connect with thousands of patients in real-time. The best part: these patients are already educated and prepared for the clinical trial process.
Comments